Dianthus Therapeutics
Clinical trials sponsored by Dianthus Therapeutics, explained in plain language.
Biotech developing complement-targeted therapies for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug could reduce need for infusions in nerve disorder Results expected Dec 2026 (estimated) May already have reported ↗
-
New drug could reduce need for infusions in nerve disorder
Disease control OngoingThis Phase 2 trial tests a drug called claseprubart (DNTH103) in 36 adults with multifocal motor neuropathy, a rare nerve condition that causes muscle weakness. Participants receive either the drug or a placebo for 15 weeks. The study looks at safety, how the drug works in the bo…
Phase 2 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug DNTH103 aims to tame muscle weakness in myasthenia gravis
Disease control OngoingThis Phase 2 study tests a drug called DNTH103 (claseprubart) in 65 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either the drug or a placebo, first through an IV and then as injections under the skin every two weeks for…
Phase 2 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC